BCM
ACHL

BML Capital Management’s Achilles Therapeutics ACHL Stock Holding History

BML Capital Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,804,921
Closed – – 29
2025
Q1 		$0 Sell
3,804,921
-295,081
-7% -$384K ﹤0.01% 31
2024
Q4 		$4.67M Hold
4,100,002
– – 2.9% 12
2024
Q3 		$4.18M Buy
4,100,002
+3,474,828
+556% +$2.78M 2.46% 11
2024
Q2 		$510K Buy
+625,174
New +$550K 0.36% 25

Other funds holding ACHL

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

BML Capital Management's ACHL Position: Q2 2025 in Review

BML Capital Management sold out of Achilles Therapeutics (ACHL) in Q2 2025, closing a stake of 3,804,921 shares.

BML Capital Management first reported a position in ACHL in Q2 2024 and held it in 4 quarters. The position peaked at $4.67M in Q4 2024. 2 funds tracked by Wall St. Rank hold ACHL as of Q2 2025.

  • BML Capital Management reported no remaining Achilles Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BML Capital Management sold 3,804,921 Achilles Therapeutics shares in Q2 2025.
  • BML Capital Management first reported a position in Achilles Therapeutics in Q2 2024 and held it in 4 quarters.
  • BML Capital Management's Achilles Therapeutics position peaked at $4.67M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2025.

Based on BML Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.